Search for a trial

Dasatinib treatment combination for fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Primary:To determine the response rate and response quality of dasatinib monotherapy or dasatinib/fludarabine combination in fludarabine refractory CLL patientsSecundaryTo asses the overall safety profile of this treatment approachTo asses event…

A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel) with Lenalidomide (Revlimid) and Dexamethasone (Decadron) in Subjects with Relapsed and/or Refractory Multiple Myeloma

The primary objective is to determine the safety and the maximum tolerated dose of dasatinib in combination with lenalidomide and low dose dexamethasone in subjects with relapsed or refractory multiple myeloma

Randomized Open-label Phase II Study of CCNU versus CCNU + Dasatinib in Patients with Recurrent Glioblastoma.

The general objectives are to assess the safety of combining dasatinib with CCNU as well as to assess activity of this combination and CCNU alone in GBM patients who have relapsed after prior treatment with temozolomide and radiotherapy

An open label, randomised, muliticentre Phase III Trial of Dasatnib (SPRYCEL®) vs standard dose Imatininb (400mg) in the treatment of subjects with newly diagnosed chronic phase Philadelphia chromosome positive chronic myeloid leukaemia (CML).

To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib

PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID
LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an
initial stop attempt : a multicenter prospective trial

Assessment of treatment-free remission (persistence of MMR) after second attempt of TKI discontinuation in patients who failed a relapsed in the EURO-SKI study or under EURO-SKI like conditions. Patients must have received at least three years of…

CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy

To demonstrate that a dose reduction of 20-33% of CYP3A4 metabolized tyrosine kinase inhibitors in patients expressing the CYP3A4*22 gene (rs35599367 C>T in intron 6) does not result in a lower exposure (Ctrough) than the wildtype group with…

A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukaemias Resistant or Intolerant to Imatinib

The main objective of this study is to estimate the rate of response to dasatinib in children and adolescents with certain types of Ph+ leukaemia either whose disease is resistant to, intolerant to or relapsed after previous imatinib therapy or are…

The therapeutical efficacy of senolytic drugs in the treatment of non-alcoholic fatty liver disease with fibrosis - the truth study

This study has been transitioned to CTIS with ID 2024-517593-21-00 check the CTIS register for the current data. To examine the effect of oral dasatinib plus quercetin on liver fibrosis as assessed by histology in individuals with biopsy-proven…

A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic Leukemia (CABL001X2101)

Primary:Determine the MTD and/or RDE(s) of ABL001:* As a single agent for CML CP and AP patients* In combination with either nilotinib or imatinib or dasatinib in CML CP and AP patients* As a single agent for CML BP patients and Ph+ ALL…